Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials

Journal of Clinical Psychiatry

Volumn 68, Issue 12, 2007, Pages 1828-1833

  Khan, Arif ^a,b,g   Schwartz, Kelly ^a   Stern, Chelsea ^a   Redding, Nick ^a   Kolts, Russell L ^c   Brown, Walter A ^d,e   Robinson, Donald S ^f  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c EASTERN WASHINGTON UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Worldwide Drug Development   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FOOD AND DRUG ADMINISTRATION; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA;

EID: 38049000234     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1201     Document Type: Article

References (19)

1. Felker B, Yazel JJ, Short D. Mortality and medical comorbidity among psychiatric patients: a review. Psychiatr Serv 1996;47:1356-1363
2. Amaddeo F, Bisoffi G, Bonizzato P, et al. Mortality among patients with psychiatric illness: a ten year case register study in an area with a community-based system of care. Br J Psychiatry 1995;166:783-788
3. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr Bull 1989;15:81-89
4. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239-245
5. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118(suppl 2):15S-22S
6. Ösby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county. Schizophr Res 2000;45:21-28
7. Enger C, Weatherby L, Reynolds RF, et al. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192:19-27
8. Stark C, MacLeod M, Hall D, et al. Mortality after discharge from long-term psychiatric care in Scotland, 1977-94: a retrospective cohort study. BMC Public Health 2003;3:30
9. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004;164:1293-1297
10. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005;25:32-41
11. Fayek M, Kingsbury SJ, Zada J, et al. Cardiac effects of antipsychotic medications. Psychiatr Serv 2001;52:607-609
12. Chong SA, Mythily, Mahendran R. Cardiac effects of psychotropic drugs. Ann Acad Med Singapore 2001;30:625-631
13. Brannon MD, Riggs JJ, Hageman WE, et al. A comparison of the cardiovascular effects of haloperidol, thioridazine and chlorpromazine HCL. Arch Int Pharmacodyn Ther 1980;244:48-57
14. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001;158:1449-1454
15. Khan A, Schwartz K. Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA Summary Basis of Approval reports. Ann Clin Psychiatry 2007;19:31-36
16. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943
17. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005;353:2335-2341
18. US Dept of Justice. Freedom of Information Act. Available at: http://www.usdoj.gov/oip/index.html. Accessibility verified July 3, 2007
19. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53